The experience of American peritoneal dialysis favored policy and its enlightenment to China

Corresponding author: Zhang Ye, 404616523@qq.com

DOI: 10.12201/bmr.202206.00011

•  

  Abstract: Objective：The purpose of this study is to study the policies of peritoneal dialysis favored policy (PD-Favored) in the United States, sort out its background and development process, then provide experience for China to promote home peritoneal dialysis. Methods: Based on scoping review, we systematically summarized the measures and effects of PD-Favored policy in the United States. Results: PD-Favored policy in the United States mainly influence the behaviors of supply and demand through the following four measures: establish the End Stage Renal Disease Prospective Payment System; Increase physicians motivation to provide peritoneal dialysis by establishing the monthly capitated payment; guide patient to adopt peritoneal dialysis by establishing waiting periods, limiting frequent dialysis, and implementing treatment options education program; implement quality incentive programs and promote technological innovation in peritoneal dialysis treatments. Conclusions: PD-Favored policy in the United States have influenced the behaviors of supply and demand by means of medical insurance payment and government regulation. It has effectively promoted the popularity of peritoneal dialysis. In the future, to promote home peritoneal dialysis, China should improve its medical insurance payment policy, adopt a multidisciplinary approach to pre-dialysis education for patients, set up the quality management target of Chinese peritoneal dialysis and promote the development of automatic peritoneal dialysis.

  Key words: End stage renal disease ；peritoneal dialysis favored policy；home peritoneal dialysis; ; 

  Submit time: 15 June 2022

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• ZHU yan, ZHENG Jie, Li Xiaoying, Yang Xiaolin, HE Yongqun. Introduction to Basic Formal Ontology and its Chinese Translation. 2020. doi: 10.12201/bmr.202007.00009

  wangyuanru, huzixin, xiejinping, shaorong. Analysis of the European Unions Orphan Drug Designation Policy and Its Enlightenment to China. 2022. doi: 10.12201/bmr.202207.00031

  Yuan Jia qi, Fan Zhi Lei, Zheng Wen Yi, Wei Yan, Chen Ying Yao. Experience of Institutionalization of Health Impact Assessment abroad and Implications for China. 2022. doi: 10.12201/bmr.202203.00009

  JiangMingzhu, Ying Xiaohua. Quantitative research of vaccine management policy in China - Text analysis based on policy instruments, policy subjects and policy points. 2022. doi: 10.12201/bmr.202212.00005

  Li Xianzhe, Ma Jiyan, Cheng Haozhe, Yang Mingfang, Huang Yangmu. Policy Diffusion in China’s Pharmaceutical R&D. 2021. doi: 10.12201/bmr.202103.00007

  SHI Zhen-yu, JIA Yan-bing, XU Jin, YUAN Bei-bei, MENG Qing-yue, HE Ping. Policy translation of health policy and systems research in China. 2020. doi: 10.12201/bmr.202006.00011

  ZhangJinsui, Humin, ChenWen, GongYichun, LI Jian-mei. Exploration and enlightenment of the content design of credit management for the basic medical insurance participants in China——Based on the content analysis of the text of credit management policy of 18 regions. 2022. doi: 10.12201/bmr.202207.00025

  gonghao, zhouluojing. Text analysis of internet medical policy in China based on Digital Mining. 2022. doi: 10.12201/bmr.202208.00005

  PEI Chen-yang, HU Lin-lin, LIU Yuan-li. Policy Evolution and Recommendations of Elderly Health Care Service in China. 2020. doi: 10.12201/bmr.202007.00026

  CHEN Tong, JIANG Rong, SHAO Rong. Research and Enlightenment on Canadian Pharmaceutical Rebates Agreements. 2021. doi: 10.12201/bmr.202101.00019

• ID	Submit time	Number	Download
  1	2022-02-20	bmr.202206.00011V1	Download

• Public  Anonymous  To author only Submit Comments